ADC Therapeutics (ADCT) to Release Quarterly Earnings on Monday

ADC Therapeutics (NYSE:ADCT) is scheduled to issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.56). The firm had revenue of $16.79 million for the quarter, compared to analyst estimates of $16.58 million. ADC Therapeutics had a negative return on equity of 1,313.37% and a negative net margin of 344.15%. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Stock Up 3.6 %

NYSE ADCT opened at $4.90 on Friday. The stock has a market cap of $405.77 million, a PE ratio of -1.68 and a beta of 1.69. The business has a 50 day moving average price of $4.59 and a two-hundred day moving average price of $2.79. ADC Therapeutics has a fifty-two week low of $0.36 and a fifty-two week high of $6.04.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ADCT shares. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 price target on shares of ADC Therapeutics in a research report on Thursday, March 14th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of ADC Therapeutics in a report on Monday, April 15th. Finally, Guggenheim reiterated a “buy” rating on shares of ADC Therapeutics in a research note on Friday, April 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.